Mode
Text Size
Log in / Sign up

Predictors of pathological upstaging in clinical stage T1 renal cell carcinoma include male gender, age, and irregular marginsCould your kidney tumor look smaller than it really is inside?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that male gender, age, and irregular margins are associated with higher risk of pathological upstaging in cT1 RCC.

This meta-analysis and systematic review assessed predictors of pathological upstaging in patients with clinical stage T1 (cT1) renal cell carcinoma. The analysis included 24,957 patients to determine factors associated with progression to pT3a disease. No specific setting or follow-up duration was reported for the included studies.

The overall incidence of pathological upstaging to pT3a was 7.46%. Several variables were identified as independent predictors of this outcome. Male gender was associated with an odds ratio (OR) of 1.067 (95% CI: 1.029–1.107; p=0.001). Advanced age showed an OR of 1.029 (95% CI: 1.02–1.038; p=0.0001), and a BMI of 1.016 (95% CI: 1.004–1.027; p=0.0001) per unit increase.

Clinically significant predictors included cT1b stage (OR: 5.865; 95% CI: 3.711–9.267; p=0.0001), presence of clinical symptoms (OR: 1.987; 95% CI: 1.439–2.744; p=0.0001), a RENAL score of 7-9 (OR: 2.480; 95% CI: 1.516–4.058; p=0.0001), necrosis on imaging (OR: 2.347; 95% CI: 1.570–3.509; p=0.0001), irregular margins (OR: 2.874; 95% CI: 1.760–4.693; p=0.0001), and hilus involvement (OR: 2.134; 95% CI: 1.367–3.333; p=0.001).

Regarding recurrence, unadjusted meta-analysis results indicated a hazard ratio (HR) of 3.50 (95% CI: 2.00–6.13). After multivariable adjustment, the HR was 2.60 (95% CI: 1.86–3.64). Safety data, adverse events, and tolerability were not reported. Limitations regarding study design and potential confounding factors were not detailed in the provided data. Current evidence suggests that nine variables, including advanced age, gender, and irregular margins, may be predictors of postoperative pathological upstaging of cT1 RCC.

Imagine looking at a map and thinking a town is small, only to find out the city sprawls much further than you realized. For patients with clinical stage T1 renal cell carcinoma, doctors often see a tumor that fits within the kidney. However, this study reveals that the cancer might actually be more advanced than the scan suggests. When surgeons remove the tumor, they sometimes find it has already grown into nearby tissues, a condition called pathological upstaging.

Researchers analyzed data from 24,957 patients to see what clues predict this hidden spread. They found that having a higher BMI, being male, or having a larger tumor within the kidney all raised the odds of the cancer being more aggressive. The strongest warning signs included irregular edges on the tumor, dead tissue visible on imaging, and involvement of the kidney's central area. These factors made it significantly more likely that the cancer would be found to have spread beyond the organ's boundary after surgery.

The study also looked at what happens after surgery. Patients with these aggressive features faced a higher risk of the cancer coming back. Even after accounting for other factors, the risk of recurrence remained higher for those with these specific tumor characteristics. This information helps surgeons understand the true nature of the disease before they make the final cut, ensuring patients are prepared for the reality of their specific situation.

What this means for you:
Certain tumor features like irregular edges and larger size predict that early-stage kidney cancer may be more advanced than scans suggest.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMar 2026
View Original Abstract ↓
BackgroundThe potential predictors and clinical implications of postoperative pathological upstaging in patients with clinical stage T1 (cT1) renal cell carcinoma (RCC) remain insufficiently characterized.MethodsThis systematic review was performed in accordance with the PRISMA guidelines. Databases including PubMed, Web of Science and Embase databases were searched. A total of 17 studies (involving 24957 patients) were included, and relevant factors were analyzed from the perspectives of patients’ baseline characteristics, pathology, and imaging findings.ResultA total of 17 studies involving 24,957 patients were included. The overall incidence of pathological upstaging was 7.46%. Through combined qualitative and quantitative analysis, we identified the following independent risk associated factors for pathological upstaging to pT3a: male gender (OR: 1.067; 95% CI: 1.029–1.107;p=0.001), age (OR = 1.029; 95% CI: 1.02–1.038;p = 0.0001), BMI (OR:1.016;95% CI: 1.004–1.027;p=0.0001),cT1b (OR: 5.865; 95% CI: 3.711- 9.267; p = 0.0001),presence of clinical symptoms(OR:1.987; 95% CI: 1.439- 2.744; p = 0.0001), RENAL score= 7-9 (OR = 2.480; 95% CI: 1.516–4.058;p = 0.0001),necrosis on imaging(OR = 2.347;95% CI: 1.570–3.509;p = 0.0001), irregular margins (OR = 2.874; 95% CI: 1.760–4.693;p = 0.0001)and Hilus involvement (OR = 2.134;95%CI: 1.367-3.333;p = 0.001).Furthermore, the unadjusted meta-analysis results indicated an increased risk of recurrence in patients who upstaged to pT3a (HR = 3.50,95% CI = 2.00-6.13). After multivariable adjustment, the association remained consistent and in the same direction (HR = 2.60,95% CI = 1.86-3.64).ConclusionCurrent evidence suggests that 9 variables, including advanced age, gender, and irregular margins may be predictors of postoperative pathological upstaging of cT1 RCC.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420250640397.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.